Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
11,466,826
-
Share change
-
+863,070
-
Total reported value
-
$442,276,430
-
Price per share
-
$38.57
-
Number of holders
-
47
-
Value change
-
+$34,041,921
-
Number of buys
-
22
-
Number of sells
-
22
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2020
As of 30 Sep 2020,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,466,826 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., FMR LLC, ORBIMED ADVISORS LLC, Logos Global Management LP, Foresite Capital Management IV, LLC, VR Adviser, LLC, BlackRock Inc., CHI Advisors LLC, Nantahala Capital Management, LLC, and Invesco Ltd..
This page lists
47
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.